Innovative Biomarkers in de Novo Parkinson's Disease

Innovative Biomarkers in de Novo Parkinson's Disease

This study aims at identifying potential new and innovative biomarkers in de novo Parkinson's disease patients. New finding will help phenotyping patients since the diagnosis of the disease and potentially also in the preclinical phase.

The investigators will use 4 different approaches in parallel:

1. detailed clinical evaluation using the current available validated clinical scales and the Dopamine transporter (DAT) SPECT imaging;
2. anatomical and perfusional brain evaluation using functional MRI;
3. cortical brain mapping and transcranial magnetic stimulation assessment using a robotized approach;
4. emotional responses study using a novel paradigm. These 4 modalities will be assessed at baseline, 1 year and 2 years follow-up.

The investigators will integrate these 4 analysis using a mathematical paradigm in order to define specific phenotype of disease and disease progression.

Inclusion Criteria:

• Parkinson's disease
• Asymmetric bradykinesia and/or resting tremor and rigidity since less than 2.5 years ;
• Hoehn & Yahr ≤ 2/5 ;
• Montreal cognitive assessment ≥ 26/30 ;

Exclusion Criteria:

• Treatment for Parkinson's disease (except selegiline and rasagiline)
• Severe visual/retinal pathology revealed during ophthalmological assessment
• Hyper-sensibility to gadolinium
• Renal failure
• Specific MRI contraindication
• Specific TMS contraindication